4 stories mentioning EVMNUpdated just now
Every FINWIRES story that references EVMN, newest first.
Evommune (EVMN) has an average rating of buy and mean price target of $29.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Evommune's (EVMN) top-line results from a phase 2b trial of EVO756 to treat adults with moderate-to-severe chronic spontaneous urticaria failed to meet the primary endpoint at any dosage, according to a statement released Monday.Shares sank 39% as intraday trading volume surged to over 5.9 million from a daily average of about 415,000.Solidion Technology (STI) said Monday it plans to opportunistically acquire shares of SpaceX (SPCX) as a long-term strategic treasury asset, using a modest portion of its cash reserves.Shares of Solidion slumped 20%, with intraday trading volume climbing to about 2.4 million from a daily average of roughly 2.8 million.Martin Marietta Materials (MLM) agreed to combine with limestone supplier Lhoist North America in a $13.5 billion deal.Shares dropped 6.6% as intraday trading volume rose to more than 759,300 from a daily average of about 509,000.Price: $15.35, Change: $-9.83, Percent Change: -39.04%
Evommune, Inc. (EVMN) has an average rating of Buy and mean price target of $52, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
